Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

While they share similarities, there are differences, particularly between the drugs semaglutide and tirzepatide.

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...